Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Controlling nanoparticle targeting: from physicochemical design to molecular recognition.

Nanomedicine (London, England)·2026

Same author

EUS-guided drainage of symptomatic postoperative fluid collections: a retrospective cohort study evaluating timing of intervention and clinical outcomes.

Surgical endoscopy·2026

Same author

Enhancing Immunotherapeutic Response in Colorectal Cancer with a Neuropilin 1-Targeting Tumor-Penetrating Peptide.

Cancer research communications·2026

Same author

Targeting the αvβ5 Integrin Modifies the TGF-β-Rich Tumor Microenvironment of Pancreatic Cancer.

Cancer research·2026

Same author

Intravenous galanin (1-16) and a GalR1 agonist attenuate allodynia in rats with spared nerve injury.

Pain reports·2026

Same author

LSTA1-GBM-2A: study protocol for an exploratory phase 2a randomised controlled trial evaluating tumour-homing peptide certepetide with temozolomide in glioblastoma multiforme.

BMJ open·2025

Search research articles

Related Experiment Video

Updated: Jan 18, 2026

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Published on: June 23, 2020

Peptide-targeted nanoparticles for tumor therapy.

Valeria Sidorenko¹, Allan Tobi², Kazuki N Sugahara³

¹Laboratory of Precision and Nanomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14b, 50411 Tartu, Estonia; Division of GI/Endocrine Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY 10032, USA.

Journal of Controlled Release : Official Journal of the Controlled Release Society

|September 9, 2025

Summary

Tumor-homing peptides enhance nanoparticle (NP) delivery to solid tumors by targeting specific molecular markers. This targeted approach improves drug accumulation and therapeutic outcomes while minimizing off-target toxicities.

Keywords:

Nanoparticle drug delivery Targeted therapy Tumor-homing peptides Tumor-penetrating peptide in vivo phage display tumor microenvironment

More Related Videos

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Related Experiment Videos

Last Updated: Jan 18, 2026

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Published on: June 23, 2020

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Area of Science:

Biomedical Engineering
Drug Delivery
Oncology

Background:

Chemotherapeutics often cause off-target toxicities due to non-specific distribution.
Nanoparticle (NP) formulations improve drug delivery but face challenges in penetrating solid tumors.
The tumor microenvironment presents significant barriers to effective NP delivery.

Purpose of the Study:

To review the application of tumor-homing peptides for enhancing NP delivery to solid tumors.
To explore how these peptides overcome tumor microenvironmental barriers.
To assess the impact on therapeutic outcomes and reduced toxicity.

Main Methods:

Review of literature on tumor-homing peptides and NP delivery systems.
Analysis of peptide targeting mechanisms and tumor penetration strategies.
Evaluation of studies demonstrating improved tumor accumulation and therapeutic efficacy.

Main Results:

Tumor-homing peptides facilitate targeted NP accumulation in tumors by binding to specific molecular markers.
Tumor-penetrating peptides enhance NP extravasation and penetration into the tumor parenchyma.
Targeted delivery via peptides significantly reduces off-target effects compared to non-specific methods.

Conclusions:

Tumor-homing peptides are a promising strategy for improving the efficacy of NP-based cancer therapies.
Peptide-mediated delivery overcomes key challenges in reaching tumor cells deep within solid tumors.
This approach holds potential for enhanced treatment outcomes and reduced patient toxicity.